Invention Grant
- Patent Title: Frizzled-4 mutation indicator of retinopathy and intrauterine growth restriction
-
Application No.: US15656558Application Date: 2017-07-21
-
Publication No.: US11041863B2Publication Date: 2021-06-22
- Inventor: Kimberly Drenser , Michael T. Trese , Antonio Capone
- Applicant: RETINAL SOLUTIONS LLC
- Applicant Address: US MI Ann Arbor
- Assignee: RETINAL SOLUTIONS LLC
- Current Assignee: RETINAL SOLUTIONS LLC
- Current Assignee Address: US MI Ann Arbor
- Agency: Blue Filament Law PLLC
- Main IPC: G01N33/483
- IPC: G01N33/483 ; G01N33/49 ; A61K38/00 ; G01N33/68 ; A61K38/17
Abstract:
A method for determining the necessity of a pre-term birth treatment is provided based on obtaining a biological sample from a subject. The biological sample is analyzed for the presence of (P33S;P168S) Frizzled4 (Fzd4) gene variation. The subject or a fetus thereof is then treated for a proclivity to pre-term birth. The Fzd4 protein itself can also be analyzed for the (P33S;P168S) Fzd4 mutation.
Public/Granted literature
- US20180024138A1 FRIZZLED-4 MUTATION INDICATOR OF RETINOPATHY AND INTRAUTERINE GROWTH RESTRICTION Public/Granted day:2018-01-25
Information query
